346 related articles for article (PubMed ID: 26462052)
21. Synthesis and evaluation of novel thiosemicarbazone and semicarbazone analogs with both anti-proliferative and anti-metastatic activities against triple negative breast cancer.
Bai C; Wu S; Ren S; Zhu M; Luo G; Xiang H
Bioorg Med Chem; 2021 May; 37():116107. PubMed ID: 33735799
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biochemical evaluation of thiochromanone thiosemicarbazone analogues as inhibitors of cathepsin L.
Song J; Jones LM; Kumar GD; Conner ES; Bayeh L; Chavarria GE; Charlton-Sevcik AK; Chen SE; Chaplin DJ; Trawick ML; Pinney KG
ACS Med Chem Lett; 2012 Jun; 3(6):450-3. PubMed ID: 24900494
[TBL] [Abstract][Full Text] [Related]
23. Identification of new peptide amides as selective cathepsin L inhibitors: the first step towards selective irreversible inhibitors?
Torkar A; Lenarčič B; Lah T; Dive V; Devel L
Bioorg Med Chem Lett; 2013 May; 23(10):2968-73. PubMed ID: 23562595
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effect of chiral organotelluranes elicited in a murine melanoma model.
Paschoalin T; Martens AA; Omori ÁT; Pereira FV; Juliano L; Travassos LR; Machado-Santelli GM; Cunha RLOR
Bioorg Med Chem; 2019 Jun; 27(12):2537-2545. PubMed ID: 30962115
[TBL] [Abstract][Full Text] [Related]
25. Effect of cysteine proteinase inhibitors on murine B16 melanoma cell invasion in vitro.
Sever N; Filipic M; Brzin J; Lah TT
Biol Chem; 2002 May; 383(5):839-42. PubMed ID: 12108549
[TBL] [Abstract][Full Text] [Related]
26. 2,5-Diaryloxadiazoles and their precursors as novel inhibitors of cathepsins B, H and L.
Garg S; Raghav N
Bioorg Chem; 2016 Aug; 67():64-74. PubMed ID: 27285276
[TBL] [Abstract][Full Text] [Related]
27. Development of cell-active non-peptidyl inhibitors of cysteine cathepsins.
Dana D; Davalos AR; De S; Rathod P; Gamage RK; Huestis J; Afzal N; Zavlanov Y; Paroly SS; Rotenberg SA; Subramaniam G; Mark KJ; Chang EJ; Kumar S
Bioorg Med Chem; 2013 Jun; 21(11):2975-87. PubMed ID: 23623677
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin B and L inhibitors: a patent review (2010 - present).
Li YY; Fang J; Ao GZ
Expert Opin Ther Pat; 2017 Jun; 27(6):643-656. PubMed ID: 27998201
[TBL] [Abstract][Full Text] [Related]
29. Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies.
Elsayed HE; Ebrahim HY; Haggag EG; Kamal AM; El Sayed KA
Bioorg Med Chem; 2017 Dec; 25(24):6297-6312. PubMed ID: 29066046
[TBL] [Abstract][Full Text] [Related]
30. Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead.
Ettari R; Tamborini L; Angelo IC; Grasso S; Schirmeister T; Lo Presti L; De Micheli C; Pinto A; Conti P
ChemMedChem; 2013 Dec; 8(12):2070-6. PubMed ID: 24243827
[TBL] [Abstract][Full Text] [Related]
31. The current stage of cathepsin B inhibitors as potential anticancer agents.
Kos J; Mitrović A; Mirković B
Future Med Chem; 2014 Jul; 6(11):1355-71. PubMed ID: 25163003
[TBL] [Abstract][Full Text] [Related]
32. Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.
Sudhan DR; Rabaglino MB; Wood CE; Siemann DW
Clin Exp Metastasis; 2016 Jun; 33(5):461-73. PubMed ID: 27055649
[TBL] [Abstract][Full Text] [Related]
33. Pterostilbene carboxaldehyde thiosemicarbazone, a resveratrol derivative inhibits 17β-Estradiol induced cell migration and proliferation in HUVECs.
Nikhil K; Sharan S; Wishard R; Palla SR; Krishna Peddinti R; Roy P
Steroids; 2016 Apr; 108():17-30. PubMed ID: 26850466
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of novel synthetic chalcone derivatives as anti-tumor agents targeting Cat L and Cat K.
Wang Y; Xue S; Li R; Zheng Z; Yi H; Li Z
Bioorg Med Chem; 2018 Jan; 26(1):8-16. PubMed ID: 29223717
[TBL] [Abstract][Full Text] [Related]
35. Matrigel influences morphology and cathepsin B distribution of prostate cancer PC3 cells.
Gopal P; Rehman RU; Chadha KS; Qiu M; Colella R
Oncol Rep; 2006 Aug; 16(2):313-20. PubMed ID: 16820909
[TBL] [Abstract][Full Text] [Related]
36. 3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors.
Zhou NE; Guo D; Thomas G; Reddy AV; Kaleta J; Purisima E; Menard R; Micetich RG; Singh R
Bioorg Med Chem Lett; 2003 Jan; 13(1):139-41. PubMed ID: 12467634
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of papain-family cathepsin L-like cysteine protease inhibitors containing a 1,4-benzodiazepine scaffold as antiprotozoal agents.
Ettari R; Pinto A; Tamborini L; Angelo IC; Grasso S; Zappalà M; Capodicasa N; Yzeiraj L; Gruber E; Aminake MN; Pradel G; Schirmeister T; De Micheli C; Conti P
ChemMedChem; 2014 Aug; 9(8):1817-25. PubMed ID: 24919925
[TBL] [Abstract][Full Text] [Related]
38. Tellurium-based cysteine protease inhibitors: evaluation of novel organotellurium(IV) compounds as inhibitors of human cathepsin B.
Cunha RL; Urano ME; Chagas JR; Almeida PC; Bincoletto C; Tersariol IL; Comasseto JV
Bioorg Med Chem Lett; 2005 Feb; 15(3):755-60. PubMed ID: 15664852
[TBL] [Abstract][Full Text] [Related]
39. Dipeptidyl Enoates As Potent Rhodesain Inhibitors That Display a Dual Mode of Action.
Royo S; Rodríguez S; Schirmeister T; Kesselring J; Kaiser M; González FV
ChemMedChem; 2015 Sep; 10(9):1484-7. PubMed ID: 26179752
[TBL] [Abstract][Full Text] [Related]
40. SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
Raghav N; Singh M
Bioorg Med Chem; 2014 Aug; 22(15):4233-45. PubMed ID: 24913985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
